A 42-year-old female with body weight loss, finger tremors and ocular discomfort was diagnosed with Graves' disease complicated with ophthalmopathy. Thiamazole therapy rapidly improved her hyperthyroidism. However, she was admitted to our hospital because her eye symptoms acutely deteriorated over a period of two weeks. She had ocular immotility, exposure keratitis, conjunctival edema, severe proptosis and visual impairment with a high titer of serum thyroid-stimulating antibody (TSAb). Methylprednisolone pulse therapy at a dose of 500 mg/day improved her eye symptoms. Although the mechanism of the progression of Graves' ophthalmopathy has not yet been elucidated, special attention should be paid to the occurrence of ophthalmopathy even after the initiation of thiamazole therapy.
Introduction
Graves' ophthalmopathy (GO) is an autoimmune ocular disease that is characterized by orbital inflammation. This condition, which can affect the vision, occurs as a complication in almost half of patients with Graves' disease. The radioiodine therapy that is commonly administered for the treatment of Graves' disease has been recognized to be a risk factor for the appearance or worsening of ophthalmopathy (1) . We herein report a case of Graves' disease in which complicating GO worsened rapidly after the commencement of thiamazole administration.
Case Report
A 42-year-old woman with proptosis and diplopia was admitted to our hospital. Six months earlier, she had noticed finger tremors and had unintentionally lost 18 kg of body weight within 4 months. Bilateral ocular discomfort occurred three months before admission. Her primary physician pointed out high-grade hyperthyroidism, based on the following results: thyrotropin (TSH) <0.003 μU/mL, free triiodothyronine (FT3) >20 pg/mL and free thyroxine (FT4) > 7 ng/dL. The patient was diagnosed with Graves' disease due to the presence of serum anti-TSH receptor antibodies. At that point, she had no abnormal findings that would indicate either conjunctival or ocular infection. The administration of thiamazole rapidly improved the hyperthyroidism, and the administered dose was thus reduced from 30 to 15 mg/day. In contrast, the proptosis and diplopia deteriorated immediately following the initiation of thiamazole therapy. Glucocorticoid therapy with prednisolone at 15 mg/day was not effective for suppressing the rapid progression of ophthalmopathy. The patient was then admitted to our hospital to be treated for GO. She presented with ocular motility disorder, exposure keratitis, conjunctival injection and edema, severe proptosis (right: 24 mm, left: 21 mm) and visual impairment [right: 0.01, left: 0.15 (Fig. 1A) ]. She could not close her right eye at all. She had no history of either habitual or passive smoking.
The results of laboratory tests performed upon admission are shown in Table. The thyroid function tests demonstrated that the hyperthyroidism had been improved by the thiama- zole therapy (FT3: 4.17 pg/mL, FT4: 1.55 ng/dL), although the serum level of thyroid-stimulating antibody (TSAb) was still elevated to higher than 2,000%. Orbital magnetic resonance imaging (MRI) revealed bilateral proptosis and hypertrophy of the bilateral ocular muscles with high intensity by T2 images, thus indicating a high activity of bilateral GO (Fig. 2) . No compressive changes of the optic nerves were detected by MRI. The clinical activity score (CAS) is a scoring system that enables the classification of patients with GO into those with active disease and those with inactive disease based on the clinical signs of inflammation [pain, redness, swelling and impaired function (2)]. Her CAS was 6 points out of 7 (inactive range <3), thus indicating a highly active condition of the ophthalmopathy. The inflammatory findings, including the circadian changes of the symptoms and the severe chemosis (conjunctival edema) in the right eye (Fig. 1A) , led to an assignment of an inflammatory index of 8 points (right) and 7 points (left) out of 10 (2). Methylprednisolone pulse therapy (three courses of 500 mg/day for three days) was initiated immediately after admission in order to treat the severely active GO (Fig. 3) . Her ocular symptoms were dramatically improved by the intravenous steroid therapy (Fig. 1B) . Her visual acuity was also improved to 0.5 (right) and 0.8 (left), and she was discharged with a CAS of 0.
Discussion
Immunosuppressive therapy is effective for active GO, and an oral glucocorticoid is generally selected as the immunosuppressive agent to be administered first. However, inactive and/or fixed GO cases hardly respond to various immunosuppressive treatments, including steroid treatments, despite their severe symptoms. It is therefore important to measure the activity as well as the severity of GO before the initiation of treatment. In this case, the CAS and the results of MRI showed a high activity of ophthalmopathy. The firstline treatment for patients with severe and active GO is intravenous high-dose glucocorticoids. Some randomized trials have shown that intravenous glucocorticoid therapy was more effective with fewer adverse events than oral glucocorticoid therapy (3, 4) . While a detailed regimen of intravenous glucocorticoid therapy has not yet been well established, a previous study showed that serious adverse events occurred only in patients who were treated with daily and/or alternate single doses higher than 0.5 g (5). That study suggested that the total cumulative dose of glucocorticoid should not exceed 8 g. We treated the present patient with methylprednisolone at 0.5 g/day for three days a week, and repeated the regimen for a total of three courses. No adverse events, including liver dysfunction or cardiovascular disorder, occurred during the treatment. Her ocular symptoms and visual acuity improved dramatically during the steroid therapy.
Previous studies have revealed that radioiodine therapy for Graves' disease may result in the onset or worsening of GO more frequently than would treatment with anti-thyroid drugs (1, 6, 7) . Some studies have suggested that the deterioration of GO after radiotherapy might be related to the release of thyroid antigens as a result of radiation injury as well as to the autoimmune responses that are directed toward antigens that are shared by the thyroid and the orbit (8) . Results showing that steroid prophylaxis is effective for preventing a deterioration of GO in patients who are treated with radioiodine therapy have also suggested that autoimmune responses play a central role in the progression of GO (6, 9) . However, the cause of radiotherapy-induced deterioration of GO has yet to be elucidated. Among the patients treated with anti-thyroid drugs, ophthalmopathy was reportedly improved in 3 of 148 patients (2%) and was worsened in 4 patients (3%) following the treatment (1) . In the present case, GO worsened rapidly five days after the initiation of the anti-thyroid drug treatment. A smoking habit is also regarded as a risk factor for the development of GO (10); however, the present patient had no history of smoking.
Other unknown factors may have contributed to the development or progression of GO in this case. TSAb directly binds to the TSH receptor on orbital fibroblasts, and the level of circulating TSAb has been shown to correlate with the disease activity and severity of GO (11) . The markedly high titer of serum TSAb (>2,000%) that was observed in this case might have been associated with the potential for worsening GO after the initial treatment. A high FT3 concentration before treatment has also been reported to be a risk factor for the deterioration of ophthalmopathy (7) . Our patient showed a high serum FT3 level (>20.0 pg/mL), which was rapidly decreased by the thiamazole treatment. The rapid release of thyroid hormones and thyroid antigens from the destroyed thyroid tissues could have enhanced TSAb activity, thus leading to the acute worsening of complicated ophthalmopathy. The autoimmunity of TSAb toward orbital cells might have been affected by the anti-thyroidal drug therapy (11) . In any case, special attention should be paid to the appearance of ophthalmopathy in patients with Graves' disease complicated with GO who have high serum levels of TSAb and FT3, even if these patients are already undergoing anti-thyroid drug treatment. Further study is needed to clarify the clinical relationship between the alteration of thyroid hormone levels and the changes in GO.
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